BRPI0606506A2 - polipeptìdeos de yersinia spp. e métodos de uso - Google Patents

polipeptìdeos de yersinia spp. e métodos de uso

Info

Publication number
BRPI0606506A2
BRPI0606506A2 BRPI0606506-6A BRPI0606506A BRPI0606506A2 BR PI0606506 A2 BRPI0606506 A2 BR PI0606506A2 BR PI0606506 A BRPI0606506 A BR PI0606506A BR PI0606506 A2 BRPI0606506 A2 BR PI0606506A2
Authority
BR
Brazil
Prior art keywords
polypeptides
methods
yersinia spp
yersinia
spp
Prior art date
Application number
BRPI0606506-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Daryll A Emery
Darren E Straub
Laura Wonderling
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Publication of BRPI0606506A2 publication Critical patent/BRPI0606506A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0291Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0606506-6A 2005-01-21 2006-01-20 polipeptìdeos de yersinia spp. e métodos de uso BRPI0606506A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64610605P 2005-01-21 2005-01-21
PCT/US2006/002474 WO2006079076A2 (en) 2005-01-21 2006-01-20 Yersinia spp. polypeptides and methods of use

Publications (1)

Publication Number Publication Date
BRPI0606506A2 true BRPI0606506A2 (pt) 2009-06-30

Family

ID=36649588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606506-6A BRPI0606506A2 (pt) 2005-01-21 2006-01-20 polipeptìdeos de yersinia spp. e métodos de uso

Country Status (12)

Country Link
US (8) US8563004B2 (enExample)
EP (3) EP2431382A1 (enExample)
JP (3) JP2008528512A (enExample)
CN (1) CN101142230A (enExample)
AU (1) AU2006206234B2 (enExample)
BR (1) BRPI0606506A2 (enExample)
CA (1) CA2595163A1 (enExample)
DK (1) DK1848732T3 (enExample)
ES (1) ES2588010T3 (enExample)
MX (1) MX2007008723A (enExample)
NZ (1) NZ556651A (enExample)
WO (1) WO2006079076A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
ES2279511T3 (es) * 1994-02-09 2007-08-16 Epitopix Llc Inmunizacion activa utilizando una proteina receptor de sideroforo.
BR0206293B1 (pt) * 2001-01-03 2015-01-20 Epitopix Llc “composições compreendendo polipeptídeos receptores de sideróforos e porinas de micróbio gram-negativo, bem como métodos de isolar polipeptídeos de membrana externa
BRPI0414267A (pt) 2003-09-19 2006-11-21 Epitopix Llc polipeptìdeos de campilobacter e métodos de uso
MX2007008723A (es) 2005-01-21 2007-09-12 Epitopix Llc Polipeptidos de yersinia spp y metodos de uso.
CN107325165A (zh) * 2011-05-31 2017-11-07 和黄生物膜医疗解决方案有限公司 细胞聚集体的分散和脱离
US9631221B1 (en) 2011-09-02 2017-04-25 Becton, Dickinson And Company Identification of microorganisms using MALDI-TOF-MS on-plate extraction
KR101948400B1 (ko) * 2011-12-29 2019-02-14 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용
JP6141205B2 (ja) * 2012-02-13 2017-06-07 国立大学法人京都工芸繊維大学 窒化ケイ素(Si3N4)親和性ペプチド、及びその利用
US8753643B1 (en) 2012-04-11 2014-06-17 Life-Science Innovations, Llc Spray dried compositions and methods of use
US9017953B2 (en) * 2012-05-18 2015-04-28 Washington University Biomarker and therapeutic for urinary tract infection
RU2549712C1 (ru) * 2013-11-26 2015-04-27 Федеральное казенное учреждение здравоохранения "Ростовский-на-Дону ордена Трудового Красного Знамени научно-исследовательский противочумный институт" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека CПОСОБ ВЫДЕЛЕНИЯ ИНГИБИТОРА СЕКРЕЦИИ СИДЕРОФОРОВ, СИНТЕЗИРУЕМОГО pgm- ШТАММАМИ Y. pestis И ВЫДЕЛЕННЫЙ ИНГИБИТОР
FR3024903A1 (fr) * 2014-08-14 2016-02-19 Biomerieux Sa Procede de quantification d'au moins un groupe de microorganismes par spectrometrie de masse
AU2015329723A1 (en) * 2014-10-10 2017-04-27 Rare Element Resources, Ltd. Processing for the extraction of rare earth elements
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(tnf) 수퍼패밀리 수용체 결합 분자 및 그의 용도
WO2017083367A1 (en) 2015-11-09 2017-05-18 Epitopix, Llc Polypeptides of fusobacterium and methods of use
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
MX2019009409A (es) 2017-02-10 2019-09-27 Epitopix Llc Proteinas y composiciones de inmunizacion que contienen proteinas de pasteurella y metodos de uso.
WO2021076865A1 (en) * 2019-10-18 2021-04-22 University Of Utah Research Foundation Polymeric drug delivery conjugates and methods of making and using thereof
CN113679829B (zh) * 2020-05-18 2024-01-02 北京繁易纳维科技有限公司 一种预防癌症术后复发的肿瘤疫苗及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420253A (en) 1993-09-09 1995-05-30 Willmar Poultry Company, Inc. Method for purifying egg yolk immunoglobulins
ES2279511T3 (es) 1994-02-09 2007-08-16 Epitopix Llc Inmunizacion activa utilizando una proteina receptor de sideroforo.
US5830479A (en) 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
WO1995025742A1 (en) 1994-03-22 1995-09-28 Pfizer Inc. Pasteurellaceae antigens and related vaccines
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
AU5597998A (en) * 1996-12-04 1998-06-29 Heska Corporation Recombinant plague vaccine
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6610836B1 (en) 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
US20020061569A1 (en) 2000-03-21 2002-05-23 Robert Haselbeck Identification of essential genes in prokaryotes
BR0206293B1 (pt) 2001-01-03 2015-01-20 Epitopix Llc “composições compreendendo polipeptídeos receptores de sideróforos e porinas de micróbio gram-negativo, bem como métodos de isolar polipeptídeos de membrana externa
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0127657D0 (en) 2001-11-19 2002-01-09 Microscience Ltd Virulence genes and proteins and their use
CA2489030A1 (en) 2002-08-02 2004-02-19 Glaxosmithkline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
BRPI0414267A (pt) 2003-09-19 2006-11-21 Epitopix Llc polipeptìdeos de campilobacter e métodos de uso
CN101014618B (zh) 2004-07-23 2013-01-02 诺华疫苗和诊断有限公司 抗原的寡聚装配多肽
NZ553315A (en) 2004-08-25 2009-12-24 Epitopix Llc Fusobacterium polypeptides and methods of use
MX2007008723A (es) 2005-01-21 2007-09-12 Epitopix Llc Polipeptidos de yersinia spp y metodos de uso.
EP2298795A1 (en) 2005-02-18 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
WO2006113907A2 (en) * 2005-04-20 2006-10-26 The General Hospital Corporation Escherichia coli o157:h7 proteins and uses thereof

Also Published As

Publication number Publication date
CA2595163A1 (en) 2006-07-27
EP1848732B1 (en) 2016-07-27
JP6224655B2 (ja) 2017-11-01
JP2008528512A (ja) 2008-07-31
US9221899B2 (en) 2015-12-29
AU2006206234A1 (en) 2006-07-27
CN101142230A (zh) 2008-03-12
US9109018B2 (en) 2015-08-18
US20160228527A1 (en) 2016-08-11
US20060269564A1 (en) 2006-11-30
EP2361926A2 (en) 2011-08-31
ES2588010T3 (es) 2016-10-28
EP2431382A1 (en) 2012-03-21
US8563004B2 (en) 2013-10-22
US9801932B2 (en) 2017-10-31
MX2007008723A (es) 2007-09-12
US20160051655A1 (en) 2016-02-25
US9352029B2 (en) 2016-05-31
JP6178059B2 (ja) 2017-08-09
JP2015193645A (ja) 2015-11-05
US9085612B2 (en) 2015-07-21
AU2006206234B2 (en) 2012-01-12
US20150307598A1 (en) 2015-10-29
EP1848732A2 (en) 2007-10-31
NZ556651A (en) 2010-05-28
US20110206674A1 (en) 2011-08-25
US20140170164A1 (en) 2014-06-19
US20140161838A1 (en) 2014-06-12
US20140161834A1 (en) 2014-06-12
EP2361926A3 (en) 2011-12-21
JP2013018779A (ja) 2013-01-31
WO2006079076A3 (en) 2007-03-29
US9085613B2 (en) 2015-07-21
DK1848732T3 (en) 2016-11-14
WO2006079076A2 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
BRPI0606506A2 (pt) polipeptìdeos de yersinia spp. e métodos de uso
ECSP077316A (es) Compuestos imidazo-3-il-amina bicíclicos sustituidos
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008000066A1 (es) Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
ECSP10010722A (es) Compuestos orgánicos
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CR20110245A (es) Mutantes fgf21 y uso de los mismos.
CL2011000603A1 (es) Uso de compuestos de ditiina-tetracarboximidas que sirven para combatir hongos fitopatogenos; procedimiento para combatir dichos hongos; compuestos de ditiina-tetracarboximidas; uso de compuestos de ditiina-diisoimidas; y compuestos ditiina-diisoimidas.
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
BRPI0821004A2 (pt) Composto derivado de aminopirazol, composição farmacêutica que o contem e uso deste
BRPI0716495A2 (pt) (r,r)-fenoterol e análogos de (r,r)- ou (r,s)-fenoterol, uso dos mesmos na preparação de composição farmacêutica e composição farmacêutica compreendendo o referidos compostos.
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0815079A2 (pt) Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
CR10229A (es) Derivados de 1,2,4,5,-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
CL2008001048A1 (es) Compuestos derivados de heterociclos nitrogenados; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como antibacterianos.
PA8792401A1 (es) Fenilendiaminas
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL